Navigation Links
ConjuGon raises $3.3 million to fund clinical trials

Madison, Wis.- ConjuGon, Inc., a privately-held biopharmaceutical company, has raised $3.3 million in an investment round led by Rosetta Partners, a private investment firm based in Lake Forest, Ill.

The Madison-based ConjuGon will use the capital for clinical trials of its treatment for the infections of large wounds, and to fund the developme......

Full article >>> ">Centocor.

Alicia Loffler, director of the Kellogg Center for Biotechnology at Northwestern University.

Tom Rolfs, a member of the Wisconsin Investment Partners and a partner of Red Top Capital.

Carl Spalding, pas......

Full article >>>
'"/>

Source:wistechnology.com By WTN 12/13/06


Related biology technology :

1. ConjuGon gets $730K to treat infections
2. ConjuGon lands $1 million angel investment
3. ConjuGon receives $500,000 to battle bacteria
4. ConjuGon to present at Sachs-Bloomberg Global Biotech Forum
5. ConjuGon Awarded $250,000
6. TomoTherapy raises $223 million in IPO
7. Fusion 2007: CA chief says IT complexity raises risk
8. Inline intellectual property raises legal issues
9. Biotech with Madison ties raises $21M in capital
10. Nerites raises $1 million to improve medical tech
11. Brady Corp. raises $137 million in public offering
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):